Equities

Sunshine Biopharma Inc

SBFM:NAQ

Sunshine Biopharma Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.30
  • Today's Change0.31 / 10.37%
  • Shares traded2.77m
  • 1 Year change-99.57%
  • Beta-1.0952
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sunshine Biopharma, Inc. is a Canada-based pharmaceutical company. The Company offers and researches life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has over 32 additional generic prescription drugs. In addition, the Company is conducting a proprietary drug development program which consists of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). It also operates two wholly owned subsidiaries: NoraPharma Inc., which has a portfolio of pharmaceutical products consisting of approximately 61 generic prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells non-prescription over-the-counter (OTC) products.

  • Revenue in USD (TTM)30.48m
  • Net income in USD-3.68m
  • Incorporated2006
  • Employees44.00
  • Location
    Sunshine Biopharma Inc333 Las Olas Way, Cu4 Suite 433FORT LAUDERDALE 33301United StatesUSA
  • Phone+1 (954) 515-0810
  • Fax+1 (514) 426-6101
  • Websitehttps://www.sunshinebiopharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Psyence Biomedical Ltd0.001.52m2.32m------1.53---0.0442-0.04420.00-0.39790.00------1.13--1.20-----------------------2.63------
SOHM Inc-100.00bn-100.00bn2.48m--------------------------------------------------------------
Scorpius Holdings Inc9.85m-29.57m2.51m82.00--0.0155--0.2552-183.17-200.5653.8951.920.1552--11.08120,061.60-49.90-39.37-59.65-43.1864.27---321.53-1,068.210.3127-43.940.3569--1,789.583.841.96--27.32--
Panacea Life Sciences Holdings Inc2.76m-7.67m2.67m40.00------0.9666-0.4554-0.45540.164-0.52550.15371.6210.1369,098.25-42.65-69.04---225.03-139.49-181.62-277.51-505.410.0285-2.124.79--46.59--12.33------
Sentient Brands Holdings Inc0.00-954.07k2.72m2.00---------0.0164-0.01640.00-0.03070.000.00--0.00-460.67-220.36------41.81---31,451.190.0015-2.50-----73.68--34.98------
Scisparc Ltd0.00-6.96m3.00m3.00--8.42-----1.22-1.510.000.03440.00----0.00-92.51-69.39-152.41-111.07-------527.17----0.9371--113.73---97.61------
Evoke Pharma Inc7.53m-6.53m3.12m4.00--1.17--0.414-16.23-16.2311.243.630.71280.43074.971,881,428.00-61.83-100.48-136.53-151.1096.97---86.75-480.521.22-19.910.6523--106.51--5.25------
Tonix Pharmaceuticals Holding Corp12.46m-149.01m3.19m103.00--0.0339--0.2563-110.99-110.996.164.280.10830.8436--120,951.50-129.55-59.46-157.22-65.9221.59---1,196.12-5,126.730.7181--0.1678------0.1874--320.57--
Aoxing Pharmaceutical Company Inc30.11m-1.46m3.21m339.00--0.0375--0.1065-0.0192-0.01920.39510.25070.4962.322.56---2.41-14.54-7.06-35.4576.1968.51-4.85-37.690.73680.33870.6052--26.8837.20-62.49---38.80--
Sunshine Biopharma Inc30.48m-3.68m3.36m44.00--0.1491--0.1103-194.01-194.011,017.8520.071.063.3310.19692,772.50-12.75-101.52-15.41-137.0430.4135.47-12.07-165.333.26--0.00--454.42--83.15--110.99--
Onconetix Inc1.46m-53.12m3.52m12.00------2.40-2.62-2.620.07231.270.03283.455.30121,979.20-119.09---215.11---57.21---3,629.24--0.091-11.870.2984-------176.78------
Shuttle Pharmaceuticals Holdings Inc0.00-7.20m3.70m8.00--0.5453-----10.29-10.290.003.040.00----0.00-123.53---147.27-------------4.320.5076-------112.71------
China Pharma Holdings Inc6.25m-4.40m3.88m231.00--0.5233--0.6205-0.6254-0.62540.63790.43170.4172.3423.5727,047.32-29.39-29.66-59.89-55.25-25.896.47-70.48-73.090.2449-21.220.277---13.48-10.6822.50---25.78--
Tian'an Pharmaceutical Co Ltd10.65m3.14m4.24m--0.02360.00511.160.39810.22460.22460.76111.03----------------68.54--29.51--13.3625.660.00--50.51--106.71------
Data as of Sep 19 2024. Currency figures normalised to Sunshine Biopharma Inc's reporting currency: US Dollar USD

Institutional shareholders

1.10%Per cent of shares held by top holders
HolderShares% Held
G1 Execution Services LLCas of 30 Jun 20243.85k0.31%
L1 Capital Global, Inc.as of 13 Feb 20242.64k0.22%
HRT Financial LLCas of 30 Jun 20242.25k0.18%
XTX Markets LLCas of 30 Jun 20242.20k0.18%
Jane Street Capital LLCas of 30 Jun 20241.39k0.11%
Sabby Management LLCas of 30 Jun 20241.00k0.08%
Qube Research & Technologies Ltd.as of 30 Jun 202476.000.01%
Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Jun 202450.000.00%
Merrill Lynch, Pierce, Fenner & Smith, Inc. (Invt Mgmt)as of 30 Jun 20245.000.00%
National Bank Financial, Inc.as of 30 Jun 20243.000.00%
More ▼
Data from 30 Jun 2024 - 29 Aug 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.